Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corp ADR (NQ: LEGN )

40.61 -1.99 (-4.67%)
Streaming Delayed Price Updated: 10:04 AM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Legend Biotech Corp ADR

< Previous 1 2 3 Next >
Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021
From Legend Biotech
Via Business Wire
Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901
From Legend Biotech
Via Business Wire
Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen
From Legend Biotech
Via Business Wire
Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Corporation Announces Pricing of Public Offering
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Corporation Announces Proposed Public Offering
From Legend Biotech Corporation
Via Business Wire
Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Myeloma
From Legend Biotech
Via Business Wire
Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen
From Legend Biotech Corporation
Via Business Wire
Legend Biotech to Host Hybrid KOL Event Detailing CARTITUDE Data from the 63rd American Society of Hematology (ASH) Annual Meeting
From Legend Biotech
Via Business Wire
KILL Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen
Via Business Wire
Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen
From Legend Biotech
Via Business Wire
Legend Biotech Reports Third Quarter 2021 Financial Results and Recent Highlights
From Legend Biotech
Via Business Wire
Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel, Program and First Preclinical Results for Tri-specific CAR-T at 2021 ASH
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Announces Extension of PDUFA Date for Cilta-Cel
From Legend Biotech
Via Business Wire
Legend Biotech to Host R&D Day on October 18, 2021
From Legend Biotech
Via Business Wire
Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma
From Legend Biotech
Via Business Wire
Legend Biotech to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference
From Legend Biotech
Via Business Wire
Legend Biotech Reports Second Quarter 2021 Financial Results and Recent Highlights
From Legend Biotech
Via Business Wire
Legend Biotech Announces Advancement of Global Manufacturing Infrastructure
From Legend Biotech
Via Business Wire
Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings
From Legend Biotech
Via Business Wire
U.S. Food and Drug Administration Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire
Legend Biotech to Present at the Jefferies Virtual Healthcare Conference
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Reports First Quarter 2021 Financial Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
Legend Biotech Reports New and Updated Data from BCMA CAR-T Program at 2021 ASCO and EHA Meetings
From Legend Biotech
Via Business Wire
Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.